In January 2023, TAP made an equity investment in BioInvent to "Support Clinical Development of BI-1206 for NHL Indications and BI-1808 for T-Cell Lymphoma Indications Including CTCL."
BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
BI-1206 is a novel anti-FcyRIIB antibody currently being studied in two Phase 1/2 trials, in combination with rituximab and acalabrutinib in indolent NHL (NCT03571568) and in combination with pembrolizumab in solid tumors (NCT04219254).
BI-1808 is an anti-TNFR2 antibody being evaluated in a Phase 1/2a trial, as a single agent and in combination with the anti-PD-1 therapy Keytruda® (pembrolizumab) in patients with ovarian cancer and cutaneous T-cell lymphoma (NCT04752826).
For more information about BioInvent, visit www.bioinvent.com/.
Recent News
- June 11, 2026 - BI-1206 triplet achieves 83% response rate in refractory NHL with improved safety vs. SOC (EHA 2026)
- June 11, 2026 - BI-1808 delivers meaningful responses as single agent and in combination (pembrolizumab) in advanced CTCL (EHA 2026)
- December 8, 2025 - impressive data from Phase 2a of triple combination BI-1206, rituximab, and calquence in r/r NHL at ASH 2025
- December 7, 2025 - promising early Phase 2a BI-1808 monotherapy data in CTCL at ASH 2025
- April 29, 2025 - received FDA Fast Track Designation for BI-1808 for the treatment of T-cell lymphoma
- March 20, 2025 - received FDA Orphan Drug Designation for BI-1808 for the treatment of T-cell lymphoma
- January 8, 2025 - announced promising initial efficacy data from triple combination arm of BI-1206, rituximab and Calquence for the treatment of non-Hodgkin's lymphoma
- September 12, 2024 - announced enrolled the first patient in the triple combination arm of the Phase 1/2a study of its anti-FcgRIIB antibody, BI-1206 in NHL
- September 9, 2024 - announced additional positive preliminary efficacy data from its ongoing Phase 2a dose expansion study of BI-1808 as a single agent as three out of four evaluable patients achieved a partial response (PR) in the CTCL cohort of patients who had progressed after standard therapy. The patients are still on treatment.
- January 4, 2024 - announced 2024 strategic priorities, including BI-1808 and BI-1206 in blood cancers
- January 17, 2023 - announced selection as partner of the Therapy Acceleration Program® (TAP), aimed at advancing the company’s program to treat blood cancers. The partnership will include access to the unique scientific, clinical and drug development expertise as well as a strategic capital equity investment from TAP of USD 3 million.